Regulatory and search intelligence for GLP-1 and telehealth operators
What happened, where, when, and what it changes for search and content. Every brief links to its primary source, separates confirmed fact from our interpretation, and says where legal interpretation belongs. We track FDA and FTC actions, state enforcement, manufacturer litigation and platform advertising policy.
- FDA's 2026 warning letters to telehealth companies: what was cited
On 3 March 2026 FDA warned 30 telehealth companies over compounded GLP-1 marketing; 25 more followed on 16 June. The claim types cited, the primary sources, and the search and content implications for GLP-1 operators.
- The 503B bulks-list proposal: planning search for a product universe that can shrink
FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. What it would change for compounded GLP-1 availability, what is confirmed, and how a telehealth operator should plan search around a changing product universe.
- FTC and state enforcement on GLP-1 telehealth: claims, subscriptions, health data
The FTC's NextMed order (December 2025), its July 2026 complaint against Hims & Hers with Utah and California, and Connecticut's 2026 GLP-1 settlements. What was alleged, the primary sources, and what it changes for testimonials, pricing pages and tracking.
What a flag means on a GLP-1 site
We keep a dated store of the terms and claims that matter in this category, each tagged green, amber, red, changed or unknown, with the public source, the jurisdiction or platform, the effective date and a review date attached. A page that mentions a compounded product without saying it is not FDA-approved is amber until the disclosure is there. A comparison that equates a compounded product with a branded one is red, because FDA cited exactly that in 2026. A state-availability claim is unknown until your counsel confirms it. The check runs over titles, descriptions, headings, body copy, tables, FAQs, structured data, alt text, anchors and calls to action before anything reaches you, and its output is always a review request with the rule and source, never a verdict. Our peptide practice keeps its own briefs at PeptidesSEO.
GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.